Drug Trial Radar · NCT03392779
Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics
Last checked: Nov 19, 2026Latest source record: Aug 13, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
94
Actual
Start
Jan 5, 2018
Primary completion
Dec 21, 2018
Study completion Mar 22, 2019
Sponsor
- Lead sponsor
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 8, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability and pharmacokinetics (PK) of escalating single- and multiple-oral doses of ZSP1601 on fasted condition, and characterize PK of ZSP1601 on an empty stomach (fasted condition) and following a high fat, high calorie meal (fed condition) in a 2-period, 2-sequence manner. The study will be conducted in 3 parts (Ascending single dose, multiple dose and food effect). Participants will receive either ZSP1601 or placebo .
Conditions
- Nonalcoholic Steatohepatitis (NASH)
Interventions
ZSP1601 25 mgDrug
ZSP1601 tablet administered orally once daily under fasted condition
Placebo 25mgDrug
Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
ZSP1601 50 mgDrug
ZSP1601 tablet administered orally once daily under fasted condition
Placebo 50 mgDrug
Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
ZSP1601 100 mgDrug
ZSP1601 tablets administered orally once daily in the fasting state
Placebo 100 mgDrug
Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state
ZSP1601 175 mgDrug
ZSP1601 tablets administerekd orally once daily under fasted condition
Placebo 175 mgDrug
Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
ZSP1601 275 mgDrug
ZSP1601 tablets administered orally once daily in the fasting state
Placebo 275 mgDrug
Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state
ZSP1601 350 mgDrug
ZSP1601 tablets administered orally once daily under fasted condition
Placebo 350mgDrug
Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
ZSP1601 100 mgDrug
ZSP1601 tablets administered orally once daily under fasted or fed condition
Placebo 100mgDrug
Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition
ZSP1601 50 mgDrug
ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
Placebo 50 mgDrug
Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
ZSP1601 100 mgDrug
ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
Placebo 100 mgDrug
Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and severity of treatment-emergent adverse events (TEAEs) and Serious Adverse Events(SAE) following oral doses(single,multiple and food effect)of ZSP1601 and placebo.Time frame: SAD Group: Up to 4 days, MAD: Up to 17days, FE group: Up to 11 days after first dose
- Concomitant MedicationTime frame: UP to 4, 17, 11 days for SAD, MAD, FE part respectively
- Clinical Laboratory Abnormalities(Blood routine test, serum biochemical test, conventional coagulation examinations, urine examination ) post dose of ZSP1601 and placebo.Time frame: UP to 4, 17, 11 days for SAD, MAD, FE part respectively
- 12-lead ECG Abnormalities following oral dosing of ZSP1601 and placebo.Time frame: UP to 4, 17, 11 days for SAD, MAD, FE part respectively
- Vital signs Abnormalities following oral dosing of ZSP1601 and placebo.Time frame: UP to 4, 17, 11 days for SAD, MAD, FE part respectively
- Physical examination Abnormalities following oral dossing of ZSP1601 and placebo.Time frame: UP to 4, 17, 11 days for SAD, MAD, FE part respectively
- Cardiac color ultrasound(UCG) Abnormalities following multiple oral doses of ZSP1601 and placebo.Time frame: Screening, Day17
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Hospital of Jilin University
Changchun, Jilin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.